Key Efficacy Results of NORA520 Phase II Clinical Trial for the Treatment of Postpartum Depression (PPD)

Name or Code of Investigational New Drug: NORA520

Indication: NORA520 is an oral prodrug intended for the treatment of central nervous system disorders, such as postpartum depression (PPD) and major depressive disorder (MDD).

Planned Development Phases: Phase II clinical trial.

Current Development Status

(Please indicate whether the current phase involves filing an application / obtaining approval / failure to obtain approval; if not approved, explain the associated risks and the company’s response measures; also describe future business directions and cumulative R&D expenses.)

(1) Application Filed / Approved / Not Approved / Results of Clinical Trials at All Phases (Including Interim Analyses) / Other Major Events Affecting Drug Development

The U.S.-based Phase II clinical trial of NORA520 for the treatment of postpartum depression (PPD) has obtained the statistical results for the primary efficacy endpoint. The difference between the treatment groups and the placebo group did not reach statistical significance.

I. Study Title: 

A randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy, safety, and tolerability of oral NORA520 in adult women with severe postpartum depression.

II. Study Objectives:

• ‧To evaluate the safety and tolerability of NORA520 in patients with severe postpartum depression (PPD).
• ‧To determine whether NORA520 can reduce depressive symptoms in patients with severe PPD.
  
• ‧To assess drug-related pharmacokinetic parameters in plasma and breast milk.
  

III. Study Population: 

A total of 93 adult female patients with severe PPD were enrolled and randomized in a 1:1:1 ratio into the placebo group and two different dosing-frequency NORA520 treatment groups. Subjects received inpatient oral treatment for three days beginning with the first dose.

IV. Primary Efficacy Endpoint:

Change from baseline in the HAM-D17 total score on Day 4 compared with placebo.

• ‧Placebo group: mean reduction of 14.4 points on Day 4
• ‧NORA520 Treatment Group (1): mean reduction of 14.5 points on Day 4
• ‧NORA520 Treatment Group (2): mean reduction of 13.8 points on Day 4
  
• ‧Combined NORA520 groups: mean reduction of 14.1 points on Day 4

The study utilized a closed testing procedure to control for statistical bias arising from multiplicity. 

The combined NORA520 groups did not demonstrate a statistically significant difference compared with placebo (p = 0.72).

V. Safety Evaluation:

No serious adverse events (SAEs), deaths, life-threatening adverse events, or adverse events resulting in hospitalization or prolonged hospitalization occurred during the study. A small number of subjects experienced somnolence, but the incidence was comparable between the treatment and placebo groups. Overall tolerability was favorable, indicating that NORA520 exhibits good short-term safety.

A single clinical trial—whether for primary or secondary endpoints—is insufficient to determine the ultimate success or failure of future drug development and commercialization. Investors should evaluate the information prudently and exercise caution.

(2) If Approval Was Not Obtained or if Clinical Results Did Not Achieve Statistical Significance: Risks and Response Measures

The company is conducting a comprehensive assessment of potential factors contributing to differences between expected and observed results, including analyses of efficacy endpoints, subgroup evaluations, and plasma drug concentration data.

Future Business Direction 

Not applicable.

To safeguard future marketing strategies and protect investor interests, such information will not be disclosed.

Postpartum depression affects approximately 10–20% of new mothers. Currently, only one approved treatment is available for PPD, indicating significant unmet medical needs.

According to Fortune Business Insights, the global PPD market is projected to grow from USD 79.9 million in 2024 to USD 970 million by 2032, with a compound annual growth rate (CAGR) of 36.7%.

Based on 2021 U.S. prevalence data for major depressive disorder (MDD), approximately 21 million U.S. adults experienced at least one major depressive episode, representing 8.3% of the adult population (10.3% among women and 6.2% among men).

According to GlobalData, the global MDD market—valued at USD 8.8 billion in 2019—is expected to reach USD 14.4 billion by 2029.

None.